Valeant Pharmaceuticals Intl Inc. With Papa Is a Great Buy

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) has been a tough stock to own up until a few months ago. Here’s why I think investors should consider the beaten-up pharma firm again.

| More on:
The Motley Fool

Many smart investors have never been fans of Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX), even before the whole scandal and crash that happened after Valeant was the hottest stock in town with the highest market cap on the TSX. Something seemed fishy with its debt-fueled growth-by-acquisition strategy, and eventually, the house of cards came tumbling down.

Those who got caught up in the hype lost their shirts. Valeant has also been a very tough pill to swallow for contrarians trying to catch a bottom over the past few years as the issues kept piling up. But with new CEO Joseph Papa on board with his turnaround strategy, it may finally be time to pick up shares of VRX.

Bill Ackman’s series of unfortunate investment decisions

Activist investor Bill Ackman held on to his shares on the way down until he suddenly decided to throw in the towel after many months of pain. There was just too much effort needed to turn the business around, and that was one of his primary reasons for finally deciding to dump his stake. It seemed that no sustainable bottom could be formed in Valeant, but by the time Ackman gave up, he’d already lost most of his original investment.

Ackman threw in the towel at the worst possible time; shares of VRX surged over 95% from April’s low to June’s high. The timing wasn’t as bad as his initial entry into the stock before the collapse or his decision to buy more shares after the first plunge, but I think there was plenty of value to be had.

Re-gaining everything that Ackman originally lost is out of the question, but Valeant appears to be back on the right track with Mr. Papa at the helm. Mr. Papa had a tough task in front of him, but his decision to find good deals for the company’s non-core assets appears to be a winning long-term turnaround strategy.

Papa versus the mountain of debt

Chipping away at US$30 billion of debt is a daunting task for anyone, but Mr. Papa made it clear that he doesn’t plan on becoming completely debt free. Mr. Papa stated that he’d like to see debt as low as US$15 billion.

At the end of Q4 2016, the company’s debt-to-equity ratio was at 9.47. At the end of the last quarter, this ratio dropped to 7.24. The company is cutting debt extremely fast; in another year or so from now, Valeant could be back to growing again. But don’t expect another greed-fueled acquisition spree; the new Valeant is planned to be a legitimate pharmaceutical company that will actually be investable.

Stay smart. Stay hungry. Stay Foolish.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Joey Frenette has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

young woman celebrating a victory while working with mobile phone in the office
Investing

3 Roaring Stocks to Hold for the Next 20 Years

These top TSX stocks are excellent long-term buys, given their multi-year growth potential and solid underlying businesses.

Read more »

Two seniors float in a pool.
Dividend Stocks

TFSA: How to Earn $1,890 in Annual Tax-Free Income

Plunk these investments into your TFSA to earn passive income and avoid the taxman.

Read more »

grow dividends
Investing

Here’s My Top 3 TSX Stocks to Buy Right Now

Even though the TSX has been rising, there are still some good bargains out there. Here are three top compounding…

Read more »

Target. Stand out from the crowd
Investing

Prediction: This Canadian Growth Stock Could Double by 2030

Alimentation Couche-Tard (TSX:ATD) is a top growth stock that could do well over the next six or so years.

Read more »

Businessman holding AI cloud
Tech Stocks

Could Investing $20,000 in Nvidia Make You a Millionaire?

Nvidia stock has made investors millionaires in the last 10 years. Is it too late to invest to become a…

Read more »

Engineers walk through a facility.
Dividend Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

AtkinsRéalis (TSX:ATRL) is one TSX stock I'd never invest in.

Read more »

money cash dividends
Stocks for Beginners

Have $500? 3 Absurdly Cheap Stocks Long-Term Investors Should Buy Right Now

If you're looking for cheap stocks, these three have a huge future ahead of them, all while costing far less…

Read more »